Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Novartis AG    NOVN   CH0012005267

NOVARTIS AG

(NOVN)
  Report
SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

NOVARTIS AG : Morgan Stanley keeps its Buy rating

10/21/2020 | 06:10am EST

In a research note published by Mark Purcell, Morgan Stanley advises its customers to buy the stock. The target price is unchanged and still at CHF 101.


© MarketScreener with dpa-AFX Analyser 2020
Stocks mentioned in the article
ChangeLast1st jan.
MORGAN STANLEY 0.57% 63.84 Delayed Quote.24.88%
NOVARTIS AG -0.37% 80.76 Delayed Quote.-11.80%
All news about NOVARTIS AG
11/29Swiss firms narrowly avoid 'Responsible Business' liability as vote divides n..
RE
11/27NOVARTIS AG : Barclays reaffirms its Sell rating
MD
11/26Business rights or human rights? Swiss vote shines spotlight on companies
RE
11/25NOVARTIS : Genmab Announces Enapotamab Vedotin Update
AQ
11/25NOVARTIS AG : Bryan Garnier maintains a Buy rating
MD
11/25NOVARTIS AG : UBS reiterates its Buy rating
MD
11/25NOVARTIS AG : Goldman Sachs remains its Buy rating
MD
11/24GLOBAL MARKETS LIVE: Tesla, Best Buy, Qantas…
11/24NOVARTIS AG : Goldman Sachs reaffirms its Buy rating
MD
11/24NOVARTIS : to Repurchase Up to $2.5 Billion in Shares
DJ
More news
Financials (USD)
Sales 2020 49 435 M - -
Net income 2020 8 326 M - -
Net Debt 2020 19 268 M - -
P/E ratio 2020 24,4x
Yield 2020 3,53%
Capitalization 204 B 204 B -
EV / Sales 2020 4,51x
EV / Sales 2021 4,16x
Nbr of Employees 110 000
Free-Float 86,9%
Chart NOVARTIS AG
Duration : Period :
Novartis AG Technical Analysis Chart | NOVN | CH0012005267 | MarketScreener
Technical analysis trends NOVARTIS AG
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Average target price 105,63 $
Last Close Price 89,59 $
Spread / Highest target 57,2%
Spread / Average Target 17,9%
Spread / Lowest Target -27,7%
EPS Revisions
Managers
NameTitle
Vasant Narasimhan Chief Executive Officer
Hans Jörg Reinhardt Independent Non-Executive Chairman
Harry Werner Kirsch Chief Financial Officer
John Tsai Chief Medical Officer
Elizabeth Theophille Chief Technology & Digital Officer
Sector and Competitors
1st jan.Capitalization (M$)
NOVARTIS AG-11.80%203 829
DAIICHI SANKYO COMPANY, LIMITED56.60%72 682
JIANGSU HENGRUI MEDICINE CO., LTD.17.92%69 850
YUNNAN BAIYAO GROUP CO.,LTD7.23%18 673
ORION OYJ-3.10%6 712
SWEDISH ORPHAN BIOVITRUM AB1.42%5 440